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There are increasing calls for better understanding of “what
works” in health care [1]. One of the means for assessing what
works is through “comparative effectiveness research” (CER)
[2]. Ideally, the needed data would come from randomized con-
trolled trials (RCTs) or from natural experiments. RCTs would
need to be large, practical clinical trials that compare interven-
tions head-to-head in real clinical settings [3,4], using novel
approaches to assess clinically relevant outcomes.
Nonexperimental studies of intended drug effects have been
criticized because confounding by indication (selective channel-
ing of patients to treatment modalities based on outcome predic-
tors such as severity of disease) can almost never be ruled out
[5,6]. Recent developments in pharmacoepidemiologic methods
limit the potential for bias, and thus increase the value of non-
experimental comparisons of intended drug effects. These
methods include instrumental variable methods [7,8], the new
user design [9], the use of a comparator drug with a similar
indication to that of the index drug [10], propensity scores [11],
and simple improvements such as eliminating immortal person-
time [12] and reducing selection bias by not censoring follow-up
when a person stops taking a drug [13,14]. Much remains to be
done, however, including the study of heterogeneity of treatment
effects at the intersection between personalized medicine and
pharmacoepidemiology. In addition, there remains an unresolved
tension between emulating RCTs (increasing internal validity
based on increasing restrictions [15]) and enhancing generaliz-
ability (external validity).
CER is an interdisciplinary endeavor in which the disciplines
are linked by the need for information and the development of
methods. The involvement of ISPOR in this enterprise is welcome.
Like drugs, the Good Research Practices proposed by the working
group of the ISPOR Health Policy Council and published in this
issue of the journal [16–18] need to be evaluated by their potential
beneﬁts and harms. The potential beneﬁts are obvious. Someone
unfamiliar with performing non-experimental comparisons of
drugs and their outcomes will ﬁnd valuable discussion in these
documents of issues to be considered. Common to all such docu-
ments, however, there is the potential for harm when the recom-
mendations are used as a cookbook without understanding their
interplay. References to standard textbooks of pharmacoepidemi-
ology [e.g., 19] could help alleviate this problem.
It is inevitable for any detailed overview to contain question-
able or outmoded recommendations. Recommendations of the
proposed documents that some experienced pharmacoepidemi-
ologists might ﬁnd arguable include:
1. The requirement to report the results from all ex ante analy-
ses. Some such analyses will have been abandoned because
the researchers discovered that they are biased.
2. The assessment of the importance of biases based on how
they affect the acceptance or rejection of the null hypoth-
esis. Biases are best measured by their effects on the mag-
nitude, direction and precision of effect-measure estimates.
3. The recommendation for propensity score models to
include variables that are only weakly related to treatment
selection (but unrelated to the outcome per the following
recommendation). It is unclear why any variable that is
unrelated to the outcome should be included in a propensity
score [20].
Some core issues in the design and analysis of non-experimental
comparisons are not addressed in enough detail. One is the
importance of the role of various “stakeholders” in CER. Another
is the distinction between confounding (e.g., by indication) and
selection bias (due, for instance, to non-adherence, drop-out of
“sick stoppers,” etc. [13]). The potential to separate these forms of
bias is one of the main advantages of the new user design [9].
Given the expected continuation of the rapid development of
pharmacoepidemiologic methods over the past 5 years, the pro-
posed Good Research Practices may become outdated very
rapidly [21]. We found no indication of how ISPOR intends to
keep these guidelines up to date. In an era of guideline prolifera-
tion, one might ask what the proposed ISPOR document will add
to the existing ones in this ﬁeld, especially the Good Pharma-
coepidemiologic Practice document published and continuously
updated by the International Society for Pharmacoepidemiology
(ISPE) [22]. Finally, harmonization of the ISPOR documents with
others, including those proposed by ISPE, the US Institute of
Medicine, the US Agency for Healthcare Research and Quality,
the UK National Institute for Health and Clinical Excellence
should be considered. Such harmonization would prevent confu-
sion and nit picking by groups opposed to CER.
In our view, the beneﬁt-to-harm balance of ISPOR’s proposed
documents on Good Research Practices favors the beneﬁt side. It
will help to spread the news that non-experimental treatment
comparisons are possible given careful design, analysis, and inter-
pretation. We congratulate ISPOR for providing guidelines for
CER that emphasize the potential beneﬁts without giving CER a
black box warning for its potential harms.
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